Intellia Submits FDA BLA for CRISPR HAE Therapy, Citing Positive Trial Data

Event summary

  • Intellia Therapeutics initiated a rolling Biologics License Application (BLA) submission to the FDA for lonvo-z (lonvoguran ziclumeran), a one-time treatment for Hereditary Angioedema (HAE).
  • Phase 3 HAELO clinical trial topline data demonstrated lonvo-z met primary and key secondary endpoints, achieving freedom from HAE attacks and ongoing therapy for most patients during a six-month observation period.
  • Lonvo-z, based on CRISPR/Cas9 technology, aims to permanently lower kallikrein and bradykinin levels by inactivating the KLKB1 gene.
  • The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation, expediting the review process, and Intellia participated in the CMC Development and Readiness Pilot program.
  • Intellia anticipates BLA completion in 2H 2026, with a potential commercial launch in 1H 2027 if approved.

The big picture

Intellia’s BLA submission represents a significant milestone for the gene editing field, potentially validating the in vivo CRISPR approach for treating genetic diseases. The success of lonvo-z could unlock a new paradigm for treating rare diseases with high unmet needs, but faces challenges related to manufacturing complexity and regulatory precedent. The HAE market, while niche, is underserved and represents a significant commercial opportunity for a curative therapy.

What we're watching

Regulatory Scrutiny
The FDA’s review of lonvo-z will be closely watched as the first in vivo CRISPR-based gene editing therapy, potentially setting precedents for future approvals in this nascent field.
Commercial Adoption
The success of lonvo-z will depend on its ability to displace existing HAE treatments and demonstrate long-term efficacy and safety, given the chronic nature of the disease.
Manufacturing Scale
Intellia’s ability to scale up manufacturing of lonvo-z to meet potential demand will be critical, given the complexity of CRISPR-based therapies and the limited number of specialized manufacturing facilities.

Related topics

Regulatory Approval